Roche/Evotec's Alzheimer's candidate fails
This article was originally published in Scrip
Roche and Evotec look set to drop their MAO-B inhibitor sembragiline from development for Alzheimer's following disappointing Phase IIb data. The product appears to be a late swansong for this mechanism of action in Alzheimer's: previous similar candidates failed around 15 years ago, and the only other investigational MAO-B inhibitors still in the running are at the preclinical stage.
You may also be interested in...
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.
A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.